341 related articles for article (PubMed ID: 33722947)
1. Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.
Schett G; Baraliakos X; Van den Bosch F; Deodhar A; Østergaard M; Gupta AD; Mpofu S; Fox T; Winseck A; Porter B; Shete A; Gensler LS
J Rheumatol; 2021 Aug; 48(8):1251-1258. PubMed ID: 33722947
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B
Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.
Rudwaleit M; Claudepierre P; Kron M; Kary S; Wong R; Kupper H
Arthritis Res Ther; 2010; 12(2):R43. PubMed ID: 20230622
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
Deodhar A; Gladman DD; McInnes IB; Spindeldreher S; Martin R; Pricop L; Porter B; Safi J; Shete A; Bruin G
J Rheumatol; 2020 Apr; 47(4):539-547. PubMed ID: 31203228
[TBL] [Abstract][Full Text] [Related]
8. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Braun J; Baraliakos X; Deodhar A; Baeten D; Sieper J; Emery P; Readie A; Martin R; Mpofu S; Richards HB;
Ann Rheum Dis; 2017 Jun; 76(6):1070-1077. PubMed ID: 27965257
[TBL] [Abstract][Full Text] [Related]
9. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.
Mease PJ; Van den Bosch F; Sieper J; Xia Y; Pangan AL; Song IH
J Rheumatol; 2017 May; 44(5):599-608. PubMed ID: 28298558
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.
Behrens F; Sewerin P; de Miguel E; Patel Y; Batalov A; Dokoupilova E; Kleinmond C; Pournara E; Shekhawat A; Jentzsch C; Wiedon A; Baraliakos X;
Rheumatology (Oxford); 2022 Jul; 61(7):2856-2866. PubMed ID: 34730795
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).
van der Heijde D; Braun J; Deodhar A; Inman RD; Xu S; Mack ME; Hsu B
Rheumatology (Oxford); 2013 Feb; 52(2):321-5. PubMed ID: 23024015
[TBL] [Abstract][Full Text] [Related]
12. A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis.
van der Horst-Bruinsma I; Miceli-Richard C; Braun J; Marzo-Ortega H; Pavelka K; Kivitz AJ; Deodhar A; Bao W; Porter B; Pournara E
Rheumatol Ther; 2021 Dec; 8(4):1775-1787. PubMed ID: 34618347
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W
Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250
[TBL] [Abstract][Full Text] [Related]
14. Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab.
Lee SH; Park W; Won Lee S; Kim HA; Choe JY; Lee SH; Lee SS; Park SH; Park MC; Sheen DH; Lee HS; Lee YA; Lee Y; Kim TH
Int J Rheum Dis; 2020 Aug; 23(9):1175-1183. PubMed ID: 32725789
[TBL] [Abstract][Full Text] [Related]
15. Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI.
Palominos PE; de Campos APB; Ribeiro SLE; Xavier RM; Xavier JW; de Oliveira FB; Guerra B; Saldanha C; Mancuso ACB; Kohem CL; Gasparin AA; Sampaio-Barros PD
Adv Rheumatol; 2019 Jun; 59(1):23. PubMed ID: 31208465
[TBL] [Abstract][Full Text] [Related]
16. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
Huang F; Sun F; Wan WG; Wu LJ; Dong LL; Zhang X; Kim TH; Sengupta R; Šenolt L; Wang Y; Qiu HM; Porter B; Haemmerle S
Chin Med J (Engl); 2020 Nov; 133(21):2521-2531. PubMed ID: 32925287
[TBL] [Abstract][Full Text] [Related]
18. Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response.
Mathew AJ; Lund ML; Pedersen MP; Rasmussen SH; Glintborg B; Loft AG; Nissen MJ; Möller B; Rodrigues AM; Santos FP; Rotar Z; Tomšič M; Relas H; Peltomaa R; Gudbjornsson B; Löve TJ; Kocaer SB; Koken Avsar A; Midtbøll Ørnbjerg L; Østergaard M
Scand J Rheumatol; 2024 Jul; 53(4):237-247. PubMed ID: 38771017
[TBL] [Abstract][Full Text] [Related]
19. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
Kavanaugh A; Mease P
J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
[TBL] [Abstract][Full Text] [Related]
20. Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
Braun J; Buehring B; Baraliakos X; Gensler LS; Porter B; Quebe-Fehling E; Haemmerle S
BMC Musculoskelet Disord; 2021 Dec; 22(1):1037. PubMed ID: 34903218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
